Novo Nordisk (NYSE:NVO) inks a three-year agreement with bluebird bio (NASDAQ:BLUE)
aimed at developing next-generation genome editing therapies for
genetic disorders, including hemophilia. The collaborative research will
leverage BLUE’s proprietary mRNA-based megaTAL technology with NVO’s
hemophilia portfolio. The initial focus will be on correcting Factor
VIII deficiency.
Financial terms are not disclosed.
https://seekingalpha.com/news/3504681-novo-nordisk-teams-bluebird-bio-gene-editing
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.